Advertisement


Guillermo Garcia-Manero, MD, on Myelodysplastic Syndromes: Luspatercept and Epoetin Alfa in Lower-Risk Disease

2023 ASCO Annual Meeting

Advertisement

Guillermo Garcia-Manero, MD, of The University of Texas MD Anderson Cancer Center, discusses phase III findings from the COMMANDS trial. Compared with epoetin alfa, luspatercept improved red blood cell transfusion independence and erythroid response, as well as the duration of response in erythropoiesis-stimulating agent–naive, transfusion-dependent patients with lower‐risk myelodysplastic syndromes (Abstract 7003).



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
The myelodysplastic syndromes are a very heterogeneous group of hematopoietic disorders, and basically, clinically patients with MDS develop cytopenias related to bone marrow failure and then in some cases an increased risk of transformation to acute leukemia. MDS is generally divided into what we call lower-risk versus high-risk disease, and we use a number of classifications such as the IPSS, the IPSR, the IPSN. But the reality is that majority of the patients will have lower-risk disease and their main characteristic at the initial presentation will be cytopenia of which anemia is the most important one. And for a significant subset of these patients, transfusion requirements are a major burden for them, basically needing transfusion that could be once a week or every so many weeks, depending on their needs. We know for a long time that one of the major needs for our patients with lower-risk transfusion-dependent MDS has been the use of drugs that could improve anemia and therefore decrease the number of transfusions needed. For many years, we have drugs that were known as erythroid stimulating agents, ESAs, that are the standard of care. These are safe compounds. We've used them for probably over three decades, but they are not very effective and their responses don't really last for a long period of time. So we've been really trying to develop new agents for anemia for our patients with low-risk MDS. So luspatercept is a drug that modulates the TGF beta pathway. This is an important component of erythropoiesis and was first tested after a number of phase one, two trials in a second line trial known as the Medalist Trial. This was a study published actually in the New England Journal with planarization attached a number of years ago for patients with a specific type of MDS known as ring sideroblastic anemia. In that study, patients had already used or quote-unquote fail an ESA, and the study was a placebo-randomized study. It got the drug approved as a second line, and it gave us a good idea of the toxicity profile of this compound. With this, we decided to move this upfront and design this command trial. This is an important study. So here in patients that had not received prior therapy, we randomized luspatercept versus an ESA, in this case appointing alpha. It's a large study, 178 patients in each arm, and the results are very clear. A primary endpoint of the study was basically to achieve this composite primary endpoint that consisted of transfusion dependency defined by being at least 12 weeks without needing a transfusion, and actually also increasing the level of hemoglobin to over 1.5 grams per deciliter. A response was defined as that, and the results are very clear. Luspatercept said basically doubled the response rate from 30% to 60% compared to the ESA. But in my opinion, even more importantly, it doubled almost the duration of response from 77 to 122 weeks. I think this is important data. The toxicity profile were very similar, and I think that this basically means that this class of agents, in this case, luspatercept, is going to likely move upfront for a majority of patients with low-risk myelodysplastic syndrome in need of transfusion. My conclusion is this is a very important step now for our patients. It's actually going to give us emphasis to continue to do research in this area and really try to see if we can bring the risk responses with other agents or combinations to maybe 100%. And I think it's going to really give us a lot of energy for a group of patients with a difficult disease to treat like myelodysplastic syndrome.

Related Videos

Lung Cancer

James Chih-Hsin Yang, MD, PhD, on Metastatic Nonsquamous NSCLC: Evaluating Pemetrexed and Platinum With or Without Pembrolizumab

James Chih-Hsin Yang, MD, PhD, of the National Taiwan University Hospital and National Taiwan University Cancer Center, discusses the latest data from the phase III KEYNOTE-789 study, which evaluated the efficacy and safety of pemetrexed plus platinum chemotherapy (carboplatin or cisplatin) with or without pembrolizumab in the treatment of adults with EGFR tyrosine kinase inhibitor–resistant, EGFR–mutated, metastatic nonsquamous non–small cell lung cancer (NSCLC) (Abstract LBA9000).

Bladder Cancer

Enrique Grande, MD, on Metastatic Urothelial Carcinoma: Updated Data From IMvigor130

Enrique Grande, MD, of The University of Texas MD Anderson Cancer Center, discusses new findings that show initial responses to induction therapy with atezolizumab plus platinum and gemcitabine did not seem to impact overall survival for patients with metastatic urothelial carcinoma. Cisplatin-treated patients appeared to derive a greater benefit with atezolizumab than did carboplatin-treated patients (Abstract 4503).

Lymphoma

Manali K. Kamdar, MD, on Primary Refractory and Early Relapsing DLBCL: Therapeutic Options

Manali K. Kamdar, MD, of University of Colorado Hospital, discusses the treatment landscape for the 30% to 40% of patients with diffuse large B-cell lymphoma (DLBCL) whose disease will relapse. Patients who experience relapse within 1 year of chemoimmunotherapy have poor outcomes with autotransplantation, but chimeric antigen receptor T-cell therapy has shown efficacy and manageable toxicity.

Lung Cancer

Rami Manochakian, MD, on NSCLC: Commentary on the ADAURA Trial of Osimertinib

Rami Manochakian, MD, of Mayo Clinic Florida, offers his perspective on the new phase III findings on osimertinib, a third-generation, central nervous system EGFR tyrosine kinase inhibitor, which demonstrated an unprecedented overall survival benefit for patients with EGFR-mutated, stage IB–IIIA non–small cell lung cancer (NSCLC) after complete tumor resection, with or without adjuvant chemotherapy (Abstract LBA3).

Prostate Cancer

Alberto Bossi, MD, on Prostate Cancer: PEACE-1 Trial Findings on Radiotherapy Plus Systemic Treatment

Alberto Bossi, MD, of Institut Gustave Roussy, discusses phase III findings showing that combining prostate radiotherapy with systemic treatment did not improve overall survival in men with de novo metastatic castration-sensitive prostate cancer and low metastatic burden. However, best outcomes (radiographic progression–free-survival and overall survival) were observed in men receiving the standard of care plus abiraterone acetate plus prednisone with radiotherapy (Abstract LBA5000).

Advertisement

Advertisement




Advertisement